All In Biotech

Drug Trial Radar · NCT07199777

A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 2025

Primary completion

Nov 2026

Study completion Mar 2027

Sponsor

Lead sponsor
SciNeuroIndustry
Sponsor type
Industry
First posted
Sep 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.

Conditions

  • Diabetic Macular Edema
  • DME

Interventions

  • SNP318Drug

    Once daily, oral administration

  • PlaceboDrug

    Once daily, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EventsTime frame: 12 weeks
  2. Central Subfield Thickness (CST)Time frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.